Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

3 hours ago 4

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 1:25 PM CDT 4 min read

On May 15, 2026, Cormorant Asset Management disclosed a caller presumption successful Dianthus Therapeutics (NASDAQ:DNTH), acquiring 950,000 shares successful an estimated $55.01 cardinal commercialized based connected quarterly mean pricing.

What happened

According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Cormorant Asset Management added a caller presumption successful Dianthus Therapeutics by purchasing 950,000 shares. The estimated transaction worth was $55.01 cardinal based connected the mean closing terms for the quarter. The quarter-end presumption was valued astatine $79.72 million, capturing some the acquisition and consequent terms movement.

What other to cognize

This was a caller presumption for Cormorant, present accounting for 4% of reported 13F AUM arsenic of March 31, 2026.
Top 5 holdings post-filing:
- NASDAQ:PRAX: $285.30 cardinal (14.4% of AUM)
- NASDAQ:BBOT: $160.01 cardinal (8.1% of AUM)
- NASDAQ:EYPT: $106.54 cardinal (5.4% of AUM)
- NASDAQ:EWTX: $102.69 cardinal (5.2% of AUM)
- NASDAQ:ERAS: $93.84 cardinal (4.7% of AUM)
As of May 14, 2026, shares of Dianthus Therapeutics were priced astatine $85.34, up 350% implicit the past twelvemonth and vastly outperforming the S&P 500, which is alternatively up astir 25%.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$85.34
Market capitalization	$4 billion
Revenue (TTM)	$2 million
Net income (TTM)	($162.8 million)

Company Snapshot

Dianthus Therapeutics develops and advances caller monoclonal antibody therapies, with DNTH103 targeting terrible autoimmune and inflammatory diseases specified arsenic generalized myasthenia gravis, multifocal centrifugal neuropathy, and chronic inflammatory demyelinating polyneuropathy.
The steadfast operates a clinical-stage biotechnology concern exemplary focused connected probe and improvement of proprietary biologic treatments.
It serves patients suffering from uncommon and terrible autoimmune and neuromuscular disorders, with superior customers expected to beryllium healthcare providers, hospitals, and specialty clinics treating these conditions.

Dianthus Therapeutics, Inc. is simply a clinical-stage biotechnology institution headquartered successful New York City, specializing successful the improvement of innovative monoclonal antibody therapies for terrible autoimmune and inflammatory diseases. The institution leverages a focused R&D attack to code unmet aesculapian needs successful uncommon neuromuscular conditions. Its strategy centers connected advancing its pb candidate, DNTH103, done objective trials to found a competitory presumption successful the specialty therapeutics market.

What this transaction means for investors

With Dianthus shares having surged 350% successful the past twelvemonth (and much than doubling past 4th alone), Cormorant inactive stepped successful aggressively, suggesting the money believes cardinal objective milestones could support driving upside.

Dianthus has fixed investors plentifulness to ticker recently. Earlier this month, the institution said it reached an aboriginal “GO” determination successful its Phase 3 CAPTIVATE proceedings aft hitting responder targets faster than expected, thing absorption framed arsenic grounds that pb cause claseprubart whitethorn person “best-in-disease” potential. The institution besides said its generalized myasthenia gravis Phase 3 proceedings remains connected way to statesman successful mid-2026, portion further information successful multifocal centrifugal neuropathy are expected aboriginal this year.

Dianthus ended the 4th with astir $1.2 cardinal successful currency aft raising astir $719 cardinal earlier this year, giving it a projected runway into 2030. That benignant of equilibrium expanse spot matters successful biotech, wherever backing hazard tin derail adjacent promising pipelines.

After specified a monolithic rally, expectations are present highly high, but this filing suggests Dianthus whitethorn person much country to run.

Read Entire Article